Resources Library
Do You Have Visibility into Your CRO’s processes?
We are cost-conscious, financially responsible, and considerate of budgets, yet understand and clearly communicate how additional activities could add value and reduce time to market.
July 6, 2021
Xtalks Webinar: ALS Biomarkers in Drug Development
Atlantic Research Group will be presenting a webinar via Xtalks on Tuesday, June 22, 2021 at 11am EST. Please register […]
May 28, 2021
Does Your CRO Value Every Single Patient?
Every patient counts. While large-scale intricately-designed studies can afford to lose patients, clinical trials for rare patient populations are not buffered for atrophy. ARG emphasizes that every patient is vital; in fact, we place the utmost importance on every data point in every study.
May 20, 2021
BPL And Atlantic Research Group Enter Into Long-term Collaboration
28 April, 2021–Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies headquartered in Elstree, UK, today announced the […]
April 28, 2021
Is Your CRO Experienced in Clinical Trials With No Clear Pathways?
ARG has “been there and done that” when it comes to operationalizing rare disease clinical trials. Our maturity can be seen in creating deep relationships, which allow us to get things done with no preexisting roadmap.
April 5, 2021
Critical Considerations for Rare & Orphan Disease Trial Planning
A Question-First Approach to Operationalizing Rare Disease Studies This Atlantic Research Group rare disease white paper is available for download […]
March 31, 2021